Literature DB >> 9706624

Early VEP and ERG evidence of visual dysfunction in autosomal recessive osteopetrosis.

D A Thompson1, A Kriss, D Taylor, I Russell-Eggitt, P Hodgkins, G Morgan, A Vellodi, E J Gerritsen.   

Abstract

Autosomal recessive (AR) osteopetrosis has a rapid course and manifests in the first months of life. Visual loss occurs because of optic nerve compromise, and more rarely retinal dysfunction (which may be a part of a primary neurodegeneration). The only curative treatment currently available is bone marrow transplantation (BMT). It has been suggested that BMT is contraindicated if AR osteopetrosis is associated with a primary neurodegeneration. Visual impairment tends to be irreversible after BMT. The young age of the patients makes reliable, objective tests of visual function especially important. We have reviewed the flash electroretinograms (ERGs) and flash and pattern visual evoked potentials (VEPs) recorded without sedation from 15 patients with AR osteopetrosis, 11 of whom were recorded longitudinally. The most frequent, early indication of visual dysfunction was a delay in the pattern or flash VEP latency. This first affects the pattern reversal VEP to small checks. Importantly this often preceded fundal changes of optic disc pallor, and evidence of optic nerve compression on neuroimaging. Only two patients had ERG evidence of retinal dysfunction affecting both rods and cones. One of these patients had a distinctive fundal appearance, but did not have evidence of associated neuronal degenerative disease. The other patient was lost to follow-up. In the patients reviewed in this study successful BMT and optic nerve decompression did not result in VEP improvement. Fundoscopy, VEP and ERG testing are indicated when the diagnosis of AR osteopetrosis is suspected and provide a useful means of monitoring visual involvement.

Entities:  

Mesh:

Year:  1998        PMID: 9706624     DOI: 10.1055/s-2007-973550

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  8 in total

Review 1.  Autosomal recessive osteopetrosis: diagnosis, management, and outcome.

Authors:  C J Wilson; A Vellodi
Journal:  Arch Dis Child       Date:  2000-11       Impact factor: 3.791

2.  Importance of neurological assessment before bone marrow transplantation for osteopetrosis.

Authors:  M Abinun; T Newson; P W Rowe; T J Flood; A J Cant
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

3.  Spontaneous optic nerve compression in the osteopetrotic (op/op) mouse: a novel model of myelination failure.

Authors:  Yoichi Kondo; Jenna M Ramaker; Abigail B Radcliff; Simona Baldassari; Joshua A Mayer; James N Ver Hoeve; Chuan-Li Zhang; Shing-Yan Chiu; Raymond J Colello; Ian D Duncan
Journal:  J Neurosci       Date:  2013-02-20       Impact factor: 6.167

Review 4.  Advances in osteoclast biology resulting from the study of osteopetrotic mutations.

Authors:  T Segovia-Silvestre; A V Neutzsky-Wulff; M G Sorensen; C Christiansen; J Bollerslev; M A Karsdal; K Henriksen
Journal:  Hum Genet       Date:  2008-11-06       Impact factor: 4.132

5.  Osteopetrorickets Presenting with Failure to Thrive and Hypophosphatemia.

Authors:  Jurhee Freese; Erin Greenup; Bhuvana Sunil; Ambika P Ashraf
Journal:  J Endocr Soc       Date:  2020-04-28

6.  Serial, Visually-Evoked Potentials for the Assessment of Visual Function in Patients with Craniosynostosis.

Authors:  Mostafa M Haredy; Alki Liasis; Amani Davis; Kathleen Koesarie; Valeria Fu; Joseph E Losee; Jesse A Goldstein; Ken K Nischal
Journal:  J Clin Med       Date:  2019-09-27       Impact factor: 4.241

7.  Diagnosis of keratoconus in a young male by electrophysiological test findings: A case report.

Authors:  Weiming Yan; Yanjin Chen; Xiaohong Chen; Qian Ye; Yutong Wang; Chuan Jiang; Xiangrong Zheng; Yunpeng Wang; Meizhu Chen
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

Review 8.  Clinical electrophysiology of the optic nerve and retinal ganglion cells.

Authors:  Oliver R Marmoy; Suresh Viswanathan
Journal:  Eye (Lond)       Date:  2021-06-11       Impact factor: 3.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.